Quotient Ltd (NASDAQ:QTNT) – Research analysts at Jefferies Financial Group cut their Q3 2019 earnings per share (EPS) estimates for Quotient in a research note issued on Monday, November 5th. Jefferies Financial Group analyst B. Couillard now expects that the company will post earnings of ($0.41) per share for the quarter, down from their previous forecast of ($0.35). Jefferies Financial Group also issued estimates for Quotient’s Q4 2019 earnings at ($0.39) EPS, FY2019 earnings at ($1.85) EPS, Q1 2020 earnings at ($0.32) EPS, Q4 2020 earnings at ($0.31) EPS and FY2020 earnings at ($1.28) EPS.
Quotient (NASDAQ:QTNT) last posted its quarterly earnings data on Monday, November 5th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). The firm had revenue of $6.25 million during the quarter, compared to analyst estimates of $5.80 million.
QTNT has been the topic of several other reports. Zacks Investment Research lowered Quotient from a “hold” rating to a “sell” rating in a research note on Friday. ValuEngine upgraded Quotient from a “hold” rating to a “buy” rating in a research note on Thursday, October 18th. Finally, BidaskClub upgraded Quotient from a “sell” rating to a “hold” rating in a research note on Tuesday, October 2nd.
Quotient stock opened at $6.50 on Thursday. Quotient has a 52 week low of $2.78 and a 52 week high of $9.02.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Millennium Management LLC bought a new position in Quotient during the second quarter valued at about $3,699,000. Point72 Asset Management L.P. bought a new position in Quotient during the second quarter valued at about $3,179,000. Bellevue Group AG increased its stake in Quotient by 190.7% during the second quarter. Bellevue Group AG now owns 319,814 shares of the company’s stock valued at $2,568,000 after acquiring an additional 209,814 shares during the period. Quantum Capital Management increased its stake in Quotient by 407.7% during the third quarter. Quantum Capital Management now owns 270,961 shares of the company’s stock valued at $2,046,000 after acquiring an additional 217,593 shares during the period. Finally, Gilder Gagnon Howe & Co. LLC bought a new position in Quotient during the second quarter valued at about $1,702,000. Hedge funds and other institutional investors own 49.19% of the company’s stock.
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.
Recommended Story: Google Finance Portfolio Tips and Tricks
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.